AR072042A1 - Compuestos de 2,3,4,5-tetrahidro-1h-pirido(4,3-b)indol y metodos de uso de los mismos - Google Patents

Compuestos de 2,3,4,5-tetrahidro-1h-pirido(4,3-b)indol y metodos de uso de los mismos

Info

Publication number
AR072042A1
AR072042A1 ARP090100234A ARP090100234A AR072042A1 AR 072042 A1 AR072042 A1 AR 072042A1 AR P090100234 A ARP090100234 A AR P090100234A AR P090100234 A ARP090100234 A AR P090100234A AR 072042 A1 AR072042 A1 AR 072042A1
Authority
AR
Argentina
Prior art keywords
substituted
unsubstituted
alkyl
independently
cycloalkyl
Prior art date
Application number
ARP090100234A
Other languages
English (en)
Inventor
David T Hung
Marina A Yurovskaya
Andrew Ahser Protter
Sarvajit Chakravarty
Rajendra Parasmal Jain
Alexander V Kurkin
Sergey O Bachurin
Nikolia S Zefirov
Original Assignee
Medivation Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40901464&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR072042(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medivation Technologies Inc filed Critical Medivation Technologies Inc
Publication of AR072042A1 publication Critical patent/AR072042A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)

Abstract

Compuestos tric¡clicos que se pueden usar para modular un receptor de histamina en un individuo. Que incluyen compuestos 2,3,4,5-tetrahidro-1H-pirido[4,3-b]indol. Tambien se proveen composiciones farmaceuticas que comprenden los compuestos, as¡ como metodos para usar los compuestos en diversas aplicaciones terapeuticas, entre las que se incluye el tratamiento de un trastorno cognitivo, un trastorno psicotico, trastorno mediado por neurotransmisores y/o un trastorno nervioso. Reivindicacion 1: Un compuesto caracterizado porque tiene la formula (1), en donde: R1 es H, hidroxilo, nitro, ciano, halo, alquilo C1-8 sustituido o no sustituido, alquenilo C2-8 sustituido o no sustituido, alquinilo C2-8 sustituido o no sustituido, perhaloalquilo, acilo, aciloxi, carbonilalcoxi, heterociclilo sustituido o no sustituido, arilo sustituido o no sustituido, heteroarilo sustituido o no sustituido, aralquilo sustituido o no sustituido, perhaloalcoxi C1-8, alcoxi, ariloxi, carboxilo, tiol, tioalquilo, amino sustituido o no sustituido, acilamino, aminoacilo, aminocarbonilamino, aminocarboniloxi, aminosulfonilo, sulfonilamino, sulfonilo o carbonilalquilenalcoxi; cada R2a y R2b es en forma independiente H, alquilo C1-8 sustituido o no sustituido, halo ciano, hidroxilo, alcoxi, nitro, o R2a y R2b se toman junto con el carbono al cual est n unidos para formar una porcion cicloalquilo o una porcion carbonilo; cada R3a y R3b es en forma independiente H, alquilo C1-8 sustituido o no sustituido, halo, ciano hidroxilo, alcoxi, nitro, o R3a y R3b se toman junto con el carbono al cual est n unidos para formar una porcion cicloalquilo o una porcion carbonilo; cada X7, X8, X9 y X10 es en forma independiente N o CR4; m y q son en forma independiente 0 o 1; n es 0 o 1; cada R4 es en forma independiente H, hidroxilo, nitro, ciano, halo, perhaloalquilo C1-8, alquilo C1-8 sustituido o no sustituido, alquenilo C2-8 sustituido o no sustituido, alquinilo C2-8 sustituido o no sustituido, arilo sustituido o no sustituido, heteroarilo sustituido o no sustituido, perhaloalcoxi C1-8, alcoxi C1-8, ariloxi, carboxilo, tiol, heterociclilo sustituido o no sustituido, aralquilo sustituido o no sustituido, tioalquilo, amino sustituido o no sustituido, acilamino, aminoacilo, aminocarbonilamino, aminocarboniloxi, aminosulfonilo, sulfonilamino, sulfonilo, carbonilalquilenalcoxi, alquilsulfonilamino o acilo; cada R8a, R8b, R8c, R8d, R8e y R8f es en forma independiente H, hidroxilo, alquilo sustituido o no sustituido o se toma junto con el carbono al cual est  unido y un R8(a-f) germinal para formar una porcion cicloalquilo; cada R10a y R10b es en forma independiente H, alquilo C1-8 sustituido o no sustituido, halo, hidroxilo, alcoxilo o R10a y R10b se toman junto con el carbono al cual est n unidos para formar una porcion cicloalquilo o una porcion carbonilo; y Q es acilamino ac¡clico o c¡clico, carbonilalcoxi, aciloxi, aminoacilo, aminocarbonilalcoxi, lactama sustituida o no sustituida o cicloalquilo sustituido o no sustituido; con la salvedad de que : (i) Q es cicloalquilo sustituido o no sustituido o una porcion lactama cuando -y solamente cuando- cada uno de m, n y q es 0; (ii) Q es acilamino c¡clico solamente cuando cada uno de m, n y q es 1; (iii) cuando Q es carbonilalcoxi, cada R8a, R8b, R8c, R8d, R8e y R8f es distinto de cicloalquilo y alquilo sustituido; (iv) el compuesto es distinto de un compuesto en la Tabla 1; y (v) el compuesto es distinto de 5-ciclohexil-2,3,4,5-tetrahidro-2-metil-1H-pirido[4,3-b]indol y 5-ciclopentil-2,3,4,5-tetrahidro-2-[(4-metil-1H-imidazol-5-il)metil]-1H-pirido[4,3-b]indol-1-ona; o una sal del mismo.
ARP090100234A 2008-01-25 2009-01-26 Compuestos de 2,3,4,5-tetrahidro-1h-pirido(4,3-b)indol y metodos de uso de los mismos AR072042A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6243008P 2008-01-25 2008-01-25
US6239408P 2008-01-25 2008-01-25
RU2008102993/04A RU2544856C2 (ru) 2008-01-25 2008-01-25 НОВЫЕ ПРОИЗВОДНЫЕ 2,3,4,5-ТЕТРАГИДРО-1-ПИРИДО[4,3-b]ИНДОЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ

Publications (1)

Publication Number Publication Date
AR072042A1 true AR072042A1 (es) 2010-08-04

Family

ID=40901464

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090100234A AR072042A1 (es) 2008-01-25 2009-01-26 Compuestos de 2,3,4,5-tetrahidro-1h-pirido(4,3-b)indol y metodos de uso de los mismos

Country Status (13)

Country Link
US (3) US9115137B2 (es)
EP (1) EP2244708B1 (es)
JP (1) JP2011510932A (es)
CN (1) CN101983059B (es)
AR (1) AR072042A1 (es)
AU (1) AU2009206246C1 (es)
BR (1) BRPI0905783A2 (es)
CA (1) CA2713997A1 (es)
CL (1) CL2009000161A1 (es)
PE (1) PE20091435A1 (es)
RU (1) RU2544856C2 (es)
UY (1) UY31614A1 (es)
WO (1) WO2009094668A1 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2007139634A (ru) * 2007-10-25 2009-04-27 Сергей Олегович Бачурин (RU) Новые тиазол-, триазол- или оксадиазол-содержащие тетрациклические соединения
RU2544856C2 (ru) 2008-01-25 2015-03-20 Сергей Олегович Бачурин НОВЫЕ ПРОИЗВОДНЫЕ 2,3,4,5-ТЕТРАГИДРО-1-ПИРИДО[4,3-b]ИНДОЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
CN102083830B (zh) 2008-03-24 2014-11-12 梅迪维新技术公司 吡啶并[3,4-b]吲哚和应用方法
JP5586577B2 (ja) * 2008-03-24 2014-09-10 メディベイション テクノロジーズ， インコーポレイテッド 架橋複素環化合物およびその使用
JP5551708B2 (ja) 2008-10-31 2014-07-16 メディベイション テクノロジーズ， インコーポレイテッド アゼピノ［４，５−ｂ］インドール化合物およびその使用方法
JP5588991B2 (ja) 2008-10-31 2014-09-10 メディベイション テクノロジーズ， インコーポレイテッド 剛性の部分を有するピリド［４，３−ｂ］インドール
US8362277B2 (en) 2009-01-09 2013-01-29 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
AU2010203356B2 (en) 2009-01-09 2015-11-26 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US9162980B2 (en) 2009-01-09 2015-10-20 Board Of Regents Of The University Of Texas System Anti-depression compounds
US9962368B2 (en) 2009-01-09 2018-05-08 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US8063032B2 (en) 2009-02-11 2011-11-22 Sunovion Pharmaceuticals Inc. Histamine H3 inverse agonists and antagonists and methods of use thereof
AU2010282990B2 (en) 2009-04-29 2015-11-05 Medivation Technologies, Inc. Pyrido [4, 3-b] indoles and methods of use
BRPI1006602A2 (pt) 2009-04-29 2019-01-15 Medivation Technologies Inc composto, método para modular um receptor de histamina em um indivíduo, composição farmacêutica, kit e método para tratar um distúrbio cognitivo ou um distúrbio induzido por pelo menos um sintoma associado com a alteração da cognição
MX2012002827A (es) * 2009-09-11 2012-04-10 Sunovion Pharmaceuticals Inc Agonistas inversos y antagonistas de histamina h3 y metodos para usar los mismos.
JP5779183B2 (ja) 2009-09-23 2015-09-16 メディベイション テクノロジーズ， インコーポレイテッド ピリド［４，３−ｂ］インドールおよび使用方法
CN102724875B (zh) 2009-09-23 2015-05-27 梅迪维新技术公司 吡啶并[3,4-b]吲哚化合物及其使用方法
CA2775129A1 (en) * 2009-09-23 2011-03-31 Medivation Technologies, Inc. Pyrido[3,4-b]indoles and methods of use
WO2011038164A1 (en) 2009-09-23 2011-03-31 Medivation Technologies, Inc. Bridged heterocyclic compounds and methods of use
US20130172320A1 (en) * 2010-02-18 2013-07-04 Sarvajit Chakravarty Pyrido [4,3-b] indole and pyrido [3,4-b] indole derivatives and methods of use
US9040519B2 (en) 2010-02-18 2015-05-26 Medivation Technologies, Inc. Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
US9034865B2 (en) 2010-02-18 2015-05-19 Medivation Technologies, Inc. Pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
WO2011103460A1 (en) 2010-02-18 2011-08-25 Medivation Technologies, Inc. Fused tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]ondole derivatives and methods of use
WO2011103448A1 (en) * 2010-02-19 2011-08-25 Medivation Technologies, Inc. Methods and compositions for treating psychotic disorders using antipsychotic combination therapy
US9187471B2 (en) 2010-02-19 2015-11-17 Medivation Technologies, Inc. Pyrido [4,3-b] indole and pyrido [3,4-b] indole derivatives and methods of use
DK2590647T3 (en) * 2010-07-07 2018-02-12 Univ Texas Pro-neurogenic compounds
JP5963758B2 (ja) * 2010-10-22 2016-08-03 コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガナイゼーション 有機エレクトロルミネッセント素子
WO2012112965A1 (en) 2011-02-18 2012-08-23 Medivation Technologies, Inc. Compounds and methods of treating diabetes
US9199985B2 (en) 2011-02-18 2015-12-01 Medivation Technologies, Inc. Compounds and methods for treatment of hypertension
WO2012112964A2 (en) 2011-02-18 2012-08-23 Medivation Technologies, Inc. PYRIDO[4,3-b]INDOLE AND PYRIDO[3,4-b]INDOLE DERIVATIVES AND METHODS OF USE
AU2012254158B2 (en) 2011-02-18 2016-02-04 Medivation Technologies, Inc. Compounds and methods of treating diabetes
EP2925129A4 (en) * 2012-08-24 2016-06-08 Univ Texas PRO-NEUROGENIC COMPOUNDS
AU2013305591B2 (en) 2012-08-24 2017-04-13 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
WO2015070237A1 (en) 2013-11-11 2015-05-14 Board Of Regents Of The University Of Texas System Neuroprotective chemicals and methods for identifying and using same
WO2015070234A2 (en) 2013-11-11 2015-05-14 Board Of Regents Of The University Of Texas System Neuroprotective compounds and use thereof
US10065951B2 (en) 2014-05-30 2018-09-04 Icahn School Of Medicine At Mount Sinai Small molecule transcription modulators of bromodomains
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
US10513515B2 (en) 2017-08-25 2019-12-24 Biotheryx, Inc. Ether compounds and uses thereof
KR102526964B1 (ko) 2018-02-26 2023-04-28 길리애드 사이언시즈, 인코포레이티드 Hbv 복제 억제제로서의 치환된 피롤리진 화합물
AU2019309894A1 (en) 2018-07-27 2021-01-28 Biotheryx, Inc. Bifunctional compounds as CDK modulators
CN111087399A (zh) * 2019-12-24 2020-05-01 温州大学新材料与产业技术研究院 一种吲哚稠合的七元内酰胺化合物的制备方法
US11897930B2 (en) 2020-04-28 2024-02-13 Anwita Biosciences, Inc. Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications
CN116546984A (zh) * 2020-09-28 2023-08-04 耶鲁大学 5-ht2a受体的选择性激动剂及其使用方法
WO2023141225A1 (en) * 2022-01-19 2023-07-27 Onsero Therapeutics Inc. Fused heterocycles as 5-ht2a receptor agonists

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5360800A (en) * 1987-09-03 1994-11-01 Glaxo Group Limited Tetrahydro-1H-pyrido[4,3-b]indol-1-one derivatives
JP2602915B2 (ja) 1987-09-03 1997-04-23 グラクソ、グループ、リミテッド ラクタム誘導体
PH25493A (en) 1987-09-03 1991-07-24 Glaxo Group Ltd 2,3,4,5-tetrahydro-2-£(imidazol-(or-5)-yl)methyl-ih-pyrido£4,3-b|indol-1-ones , derivatives having 5-ht antagonist activity 3
US5817756A (en) * 1993-09-09 1998-10-06 Scios Inc. Pseudo- and non-peptide bradykinin receptor antagonists
RU2140417C1 (ru) 1995-10-17 1999-10-27 Институт физиологически активных веществ РАН Производные гидрированных пиридо(4,3-b)индолов, способы их получения, фармацевтическая композиция и способ лечения
RU2106864C1 (ru) * 1995-10-23 1998-03-20 Николай Серафимович Зефиров Средство для лечения болезни альцгеймера
AU2003210610B2 (en) 2002-01-18 2007-11-29 Aryx Therapeutics 5-HT3 receptor antagonists and methods of use
CN1668918A (zh) * 2002-07-24 2005-09-14 基德姆生物科学有限公司 药物发现的方法
US7736889B2 (en) 2003-06-10 2010-06-15 The United States Of America As Represented By The Secretary Of The Navy Fluidic force discrimination
RU2283108C2 (ru) 2003-12-08 2006-09-10 Сергей Олегович Бачурин ГЕРОПРОТЕКТОР НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b) ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ
US20070179174A1 (en) * 2003-12-08 2007-08-02 Bachurin Sergei O Methods and compositions for slowing aging
DK1725553T3 (da) 2004-03-11 2008-08-18 Actelion Pharmaceuticals Ltd Tetrahydropyridoindolderivater
EP1863810A4 (en) * 2005-03-22 2010-03-31 Astrazeneca Ab NEW TETRAHYDRO-1H-PYRIDO [4,3-B] INDOLDERIVATE AS CB1 'RECEPTOR LIGANDS
JP2009502959A (ja) * 2005-07-28 2009-01-29 ブリストル−マイヤーズ スクイブ カンパニー セロトニン受容体アゴニストおよびアンタゴニストとしての置換テトラヒドロ−１ｈ−ピリド［４，３，ｂ］インドール
JP2009504773A (ja) 2005-08-19 2009-02-05 エラン ファーマシューティカルズ，インコーポレイテッド ガンマセクレターゼの架橋ｎ−二環式スルホンアミド阻害剤
EP1937263A2 (en) * 2005-10-04 2008-07-02 Medivation, Inc. Hydrogenated pyrido-indole compounds for the treatment of huntington ' s disease
RU2338537C2 (ru) * 2006-01-25 2008-11-20 Сергей Олегович Бачурин СРЕДСТВО ДЛЯ ЛЕЧЕНИЯ ШИЗОФРЕНИИ НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b)ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ
CA2664099A1 (en) * 2006-09-20 2008-03-27 Medivation Neurology, Inc. Methods and compositions for treating amyotrophic lateral sclerosis (als)
EP2066322A2 (en) * 2006-09-20 2009-06-10 Medivation Neurology, Inc. Hydrogenated pyrido [4,3-b] indoles such as dimebon for treating canine cognitive dysfunction syndrome
KR20090087009A (ko) 2006-10-27 2009-08-14 메디베이션 뉴롤로지 인코퍼레이티드 아이.에이. 다임본 및 도레페질을 사용하여 알츠하이머 병을 치료하기 위한 조합 요법
RU2329044C1 (ru) 2006-11-16 2008-07-20 Андрей Александрович Иващенко Лиганды 5-ht6 рецепторов, фармацевтическая композиция, способ ее получения и лекарственное средство
RU2334514C1 (ru) * 2006-12-01 2008-09-27 Институт физиологически активных веществ Российской Академии наук СРЕДСТВО ДЛЯ УЛУЧШЕНИЯ КОГНИТИВНЫХ ФУНКЦИЙ И ПАМЯТИ НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО (4,3-b) ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ
RU2340342C2 (ru) 2006-12-07 2008-12-10 Сергей Олегович Бачурин СРЕДСТВО ДЛЯ ЛЕЧЕНИЯ ОСТРЫХ И ХРОНИЧЕСКИХ НАРУШЕНИЙ МОЗГОВОГО КРОВООБРАЩЕНИЯ, В ТОМ ЧИСЛЕ ИНСУЛЬТА, НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО[4,3-b]ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ
RU2338745C1 (ru) * 2007-03-21 2008-11-20 Андрей Александрович Иващенко ЗАМЕЩЕННЫЕ 2,3,4,5-ТЕТРАГИДРО-1Н-ПИРИДО[4,3-b]ИНДОЛЫ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
CA2683453C (en) 2007-04-05 2013-06-11 Alla Chem, Llc Substituted 2,3,4,5-tetrahydro-1h-pyrido[4,3-.beta.]indoles, methods for the production and use thereof
RU2339637C1 (ru) 2007-04-05 2008-11-27 Андрей Александрович Иващенко Блокаторы гистаминного рецептора для фармацевтических композиций, обладающих противоаллергическим и аутоиммунным действием
US20100178277A1 (en) * 2007-05-25 2010-07-15 Medivation Neurology, Inc. Methods and compositions for stimulating cells
KR20100039862A (ko) 2007-06-26 2010-04-16 아스트라제네카 아베 카텝신 ｋ 억제제로서 1-시아노사이클로프로필-유도체
RU2338533C1 (ru) * 2007-06-28 2008-11-20 Сергей Олегович Бачурин СРЕДСТВО, ОБЛАДАЮЩЕЕ АНКСИОЛИТИЧЕСКИМ ДЕЙСТВИЕМ, НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b)ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ
AU2008282742A1 (en) * 2007-08-01 2009-02-05 Medivation Neurology, Inc. Methods and compositions for treating schizophrenia using antipsychotic combination therapy
WO2009039420A1 (en) 2007-09-21 2009-03-26 Medivation Neurology, Inc. Methods and compositions for treating neuronal death mediated ocular diseases
RU2007139634A (ru) 2007-10-25 2009-04-27 Сергей Олегович Бачурин (RU) Новые тиазол-, триазол- или оксадиазол-содержащие тетрациклические соединения
WO2009082268A2 (ru) 2007-12-21 2009-07-02 Alla Chem, Llc ЛИГАНДЫ α-АДРЕНОЦЕПТОРОВ, ДОПАМИНОВЫХ, ГИСТАМИНОВЫХ, ИМИДАЗОЛИНОВЫХ И СЕРОТОНИНОВЫХ РЕЦЕПТОРОВ И ИХ ПРИМЕНЕНИЕ
RU2544856C2 (ru) 2008-01-25 2015-03-20 Сергей Олегович Бачурин НОВЫЕ ПРОИЗВОДНЫЕ 2,3,4,5-ТЕТРАГИДРО-1-ПИРИДО[4,3-b]ИНДОЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
WO2009111540A1 (en) 2008-03-04 2009-09-11 Medivation Neurology, Inc. Methods for preparing pyridylethyl-substituted carbolines
CN102083830B (zh) * 2008-03-24 2014-11-12 梅迪维新技术公司 吡啶并[3,4-b]吲哚和应用方法
JP5586577B2 (ja) * 2008-03-24 2014-09-10 メディベイション テクノロジーズ， インコーポレイテッド 架橋複素環化合物およびその使用
WO2009135091A1 (en) 2008-04-30 2009-11-05 Medivation Technologies, Inc. Use of asenapine and related compounds for the treatment of neuronal or non-neuronal diseases or conditions
US20100029706A1 (en) 2008-07-30 2010-02-04 Edison Parmaceuticals, Inc. a Delaware Corporation HYDROGENATED PYRIDO[4,3-b]INDOLES FOR THE TREATMENT OF OXIDATIVE STRESS
US9625475B2 (en) 2008-09-29 2017-04-18 Abbvie Inc. Indole and indoline derivatives and methods of use thereof
UY32147A (es) 2008-09-29 2010-04-30 Abbott Lab Derivados de indol y de indolina y métodos para usarlos
JP5588991B2 (ja) 2008-10-31 2014-09-10 メディベイション テクノロジーズ， インコーポレイテッド 剛性の部分を有するピリド［４，３−ｂ］インドール
JP5551708B2 (ja) * 2008-10-31 2014-07-16 メディベイション テクノロジーズ， インコーポレイテッド アゼピノ［４，５−ｂ］インドール化合物およびその使用方法
AU2010203356B2 (en) 2009-01-09 2015-11-26 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US8362277B2 (en) 2009-01-09 2013-01-29 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US9962368B2 (en) 2009-01-09 2018-05-08 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
AU2010282990B2 (en) * 2009-04-29 2015-11-05 Medivation Technologies, Inc. Pyrido [4, 3-b] indoles and methods of use
BRPI1006602A2 (pt) * 2009-04-29 2019-01-15 Medivation Technologies Inc composto, método para modular um receptor de histamina em um indivíduo, composição farmacêutica, kit e método para tratar um distúrbio cognitivo ou um distúrbio induzido por pelo menos um sintoma associado com a alteração da cognição
WO2011014695A1 (en) 2009-07-29 2011-02-03 Medivation Technologies, Inc. New 2,3,4,5-tetrahydro-1h-pyrido[4,3-b] indoles and methods of use
WO2011038164A1 (en) * 2009-09-23 2011-03-31 Medivation Technologies, Inc. Bridged heterocyclic compounds and methods of use
CN102724875B (zh) 2009-09-23 2015-05-27 梅迪维新技术公司 吡啶并[3,4-b]吲哚化合物及其使用方法
JP5779183B2 (ja) * 2009-09-23 2015-09-16 メディベイション テクノロジーズ， インコーポレイテッド ピリド［４，３−ｂ］インドールおよび使用方法
CA2775129A1 (en) * 2009-09-23 2011-03-31 Medivation Technologies, Inc. Pyrido[3,4-b]indoles and methods of use
WO2011103460A1 (en) 2010-02-18 2011-08-25 Medivation Technologies, Inc. Fused tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]ondole derivatives and methods of use
US9040519B2 (en) * 2010-02-18 2015-05-26 Medivation Technologies, Inc. Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
US20130172320A1 (en) * 2010-02-18 2013-07-04 Sarvajit Chakravarty Pyrido [4,3-b] indole and pyrido [3,4-b] indole derivatives and methods of use
US9034865B2 (en) * 2010-02-18 2015-05-19 Medivation Technologies, Inc. Pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
WO2011103448A1 (en) 2010-02-19 2011-08-25 Medivation Technologies, Inc. Methods and compositions for treating psychotic disorders using antipsychotic combination therapy
US9187471B2 (en) * 2010-02-19 2015-11-17 Medivation Technologies, Inc. Pyrido [4,3-b] indole and pyrido [3,4-b] indole derivatives and methods of use
DK2590647T3 (en) 2010-07-07 2018-02-12 Univ Texas Pro-neurogenic compounds
AU2012254158B2 (en) 2011-02-18 2016-02-04 Medivation Technologies, Inc. Compounds and methods of treating diabetes
WO2012112965A1 (en) 2011-02-18 2012-08-23 Medivation Technologies, Inc. Compounds and methods of treating diabetes
US9199985B2 (en) 2011-02-18 2015-12-01 Medivation Technologies, Inc. Compounds and methods for treatment of hypertension
WO2012112964A2 (en) 2011-02-18 2012-08-23 Medivation Technologies, Inc. PYRIDO[4,3-b]INDOLE AND PYRIDO[3,4-b]INDOLE DERIVATIVES AND METHODS OF USE
EP2887805A4 (en) 2012-08-22 2016-08-17 Medivation Technologies Inc COMPOUNDS AND METHOD FOR TREATING BLOOD HIGH PRESSURE
WO2014031170A1 (en) 2012-08-22 2014-02-27 Medivation Technologies, Inc. Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
EP2925129A4 (en) 2012-08-24 2016-06-08 Univ Texas PRO-NEUROGENIC COMPOUNDS

Also Published As

Publication number Publication date
CL2009000161A1 (es) 2009-09-25
CN101983059A (zh) 2011-03-02
EP2244708A4 (en) 2012-01-04
BRPI0905783A2 (pt) 2017-08-22
RU2008102993A (ru) 2009-07-27
AU2009206246A1 (en) 2009-07-30
EP2244708A1 (en) 2010-11-03
CN101983059B (zh) 2014-11-05
US20130190347A1 (en) 2013-07-25
CA2713997A1 (en) 2009-07-30
US9115137B2 (en) 2015-08-25
WO2009094668A8 (en) 2010-09-10
EP2244708B1 (en) 2015-01-14
WO2009094668A1 (en) 2009-07-30
JP2011510932A (ja) 2011-04-07
US20130190348A1 (en) 2013-07-25
AU2009206246C1 (en) 2014-08-21
US20100022580A1 (en) 2010-01-28
RU2544856C2 (ru) 2015-03-20
AU2009206246B2 (en) 2014-02-20
PE20091435A1 (es) 2009-10-14
UY31614A1 (es) 2009-08-31

Similar Documents

Publication Publication Date Title
AR072042A1 (es) Compuestos de 2,3,4,5-tetrahidro-1h-pirido(4,3-b)indol y metodos de uso de los mismos
AR071284A1 (es) Compuestos heterociclicos con uniones puente y metodos para usarlos
AR071285A1 (es) Pirido[3, 4-b]indoles, una composicion farmaceutica que los comprende y su uso en el tratamiento de trastornos neurologicos.
AR127309A2 (es) Derivados de piridazinona
AR073923A1 (es) Pirido( 4,3-b) indoles que contienen restos rigidos
AR076900A1 (es) Derivados heterociclicos nitrogenados utiles como agentes antivirales, composiciones farmaceuticas que los contienen y uso de los mismos como inhibidores del vhc
AR066562A1 (es) Derivados de pirrol condensados; una formulacion farmaceutica en base al compuesto y su uso para preparar medicamentos
AR079164A1 (es) Derivados heterociclicos de indol, composiciones farmaceuticas que los comprenden y uso de los mismos para la profilaxis o tratamiento de enfermedades alergicas, inflamatorias y/o autoinmunes.
AR080785A1 (es) Derivados de imidazo[1,2-a]pirimidina ,proceso para prepararlos e intermediarios de dicha sintesis, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de patologias del sistema nervioso central,tales como esquizofrenia y parkinson, entre otros.
AR084553A1 (es) DERIVADOS IMIDAZOLICOS HETEROCICLICOS INHIBIDORES DE b-SECRETASA, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y USO DE LOS MISMOS PARA TRATAR ENFERMEDADES NEURODEGENERATIVAS, EN PARTICULAR ALZHEIMER
CO6251260A2 (es) Derivados de bifenilo conformacionalmente restringido para uso como inhibidores del virus de la hepatitis c.
AR078535A1 (es) Derivados de pirrolo[2,3-b]piridina ligandos de receptores estrogenicos, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de la osteoporosis y enfermedades del sistema nervioso central, entre otras
AR071857A1 (es) Derivados de indazol sustituidos con fenilo y benzodioxinilo, una composicion farmaceutica que los comprende y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por el receptor de glucocorticoides.
AR079553A1 (es) Derivados de diaza-espiro-[5,5]-undecanos, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos del snc, tales como trastornos del sueno y de la dependencia,entre otros.
AR038240A1 (es) Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para su preparacion
PE20121639A1 (es) Derivados de 3-hidroxi-5-arilizotiazol como moduladores de gpr40
PE20110028A1 (es) Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato
AR072906A1 (es) Nucleosidos modificados utiles como antivirales
AR067757A1 (es) Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales.
AR073924A1 (es) Azepino[4, 5-b]indoles, una composicion farmaceutica y kits que los comprenden y su uso en la modulacion de un receptor de histamina.
AR070852A1 (es) Derivados de piridazina y su uso como agentes terapeuticos
AR078786A1 (es) Derivados de la cromenona
AR063602A1 (es) Derivados de espiroindolinona, formulaciones farmaceuticas que los contienen y su uso en la obtencion de un medicamento para el tratamiento de trastornos oncologicos.
DOP2013000142A (es) Derivados de biciclo[3,2,1]octilamida y sus usos.
AR038000A1 (es) Compuesto derivado de tien[2,3-d]pirimidin-2,4(1h,3h)-diona, composicion farmaceutica, proceso para su preparacion y su uso en la fabricacion de un medicamento

Legal Events

Date Code Title Description
FB Suspension of granting procedure